Oppenheimer Reiterates Outperform on Eiger BioPharmaceuticals (EIGR) Following AASLD

November 17, 2016 11:11 AM EST
Get Alerts EIGR Hot Sheet
Price: $11.70 -1.27%

Rating Summary:
    4 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 31 | New: 42
Trade EIGR Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Oppenheimer reiterated an Outperform rating and $34.00 price target on Eiger BioPharmaceuticals (NASDAQ: EIGR) after attending AASLD. Oppenheimer detected a notable level of enthusiasm around new treatments in development for hepatitis D virus (HDV). EIGR is developing lonafarnib and PEG-IFN╬╗ for the treatment of HDV, and based on the data presented at AASLD, we believe these could become the first FDA-approved therapies for HDV.

Analyst Jay Olson commented, "We attended AASLD, and despite the almost overwhelming attention to NASH, we detected a notable level of enthusiasm around new treatments in development for hepatitis D virus (HDV). Most importantly, several abstracts featuring interim data from EIGR's LOWR HDV program were presented. This note summarizes our key takeaways from these presentations. Please see inside for complete details."

For an analyst ratings summary and ratings history on Eiger BioPharma click here. For more ratings news on Eiger BioPharma click here.

Shares of Eiger BioPharma closed at $12.45 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments

Add Your Comment